dm+d

Unassigned

New Medicines

Multiple myeloma (MM) in combination with granulocyte-colony stimulating factor (G-CSF)

Information

New molecular entity
BioLineRx
BioLineRx

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes

Category

Selective antagonist of CXCR4 chemokine receptor
Multiple myeloma is the second most common haematological cancer. It is responsible for 15-20% of deaths from haematological cancer and about 2% of all deaths from cancer. The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [2].
Multiple myeloma (MM) in combination with granulocyte-colony stimulating factor (G-CSF)
Subcutaneous infusion